Last reviewed · How we verify
omeprazole+domperidone SR
Omeprazole reduces gastric acid secretion while domperidone enhances gastric motility and accelerates gastric emptying.
Omeprazole reduces gastric acid secretion while domperidone enhances gastric motility and accelerates gastric emptying. Used for Gastroesophageal reflux disease (GERD) with gastric dysmotility, Peptic ulcer disease with impaired gastric emptying, Functional dyspepsia with acid hypersecretion.
At a glance
| Generic name | omeprazole+domperidone SR |
|---|---|
| Also known as | Omez DSR |
| Sponsor | Belarusian Medical Academy of Post-Graduate Education |
| Drug class | Proton pump inhibitor + dopamine antagonist combination |
| Target | H+/K+-ATPase (omeprazole); dopamine D2/D3 receptors (domperidone) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Omeprazole is a proton pump inhibitor that suppresses acid production by blocking H+/K+-ATPase in gastric parietal cells. Domperidone is a dopamine antagonist that increases gastric contractions and accelerates food movement through the stomach. The sustained-release formulation provides prolonged therapeutic effect, making this combination useful for acid-related disorders with concurrent gastric dysmotility.
Approved indications
- Gastroesophageal reflux disease (GERD) with gastric dysmotility
- Peptic ulcer disease with impaired gastric emptying
- Functional dyspepsia with acid hypersecretion
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: